Moderna plans to have 100 to 125 million doses of its COVID-19 vaccine available in the first quarter of 2021, the vast majority of which will go to the United States, the biotechnology company announced Thursday.
Between 85 and 100 million of the doses will be distributed in the United States, with the rest of the world receiving the remaining 15 to 25 million, the Cambridge, Massachusetts-based company said in a statement.
Moderna also confirmed that it expects to have 20 million vaccine doses available in the U.S. by the end of 2020.
The company has been working on its American supply and production chain for months, in preparation for the vaccine's expected emergency approval by US Food and Drug Administration (FDA).
For all countries outside the United States, production will take place in Switzerland.
ALSO READ:
Global COVID Death Toll Passes 1.5 Million as Nations Plan for Vaccine
Meet Moderna, the Firm Behind COVID Vaccine Breakthrough
Moderna COVID-19 Vaccine Almost 95% Effective: Trial
U.S. officials have said they plan to distribute 40 million vaccine doses by the end of the year, including those produced by Pfizer-BioNTech.
That would mean 20 million people vaccinated by the end of 2020, with each person requiring two doses.
The Moderna vaccine will be reviewed by an advisory committee of the FDA on Dec. 17, and could be greenlit for emergency approval soon after.
The FDA advisory committee meeting for the Pfizer-BioNTech vaccine, which was approved Wednesday by Britain for general use, will take place on Dec. 10
